EUCAST and CLSI: Working together towards a harmonized method for antifungal susceptibility testing

被引：27
作者：
Espinel-Ingroff A. [1 ]
Cuenca-Estrella M. [2 ]
Cantón E. [3 ]
机构：
[1] VCU Medical Center, Richmond, VA 23221
[2] Servicio de Micología, Centro Nacional de Microbiología, Instituto de Salud Carlos III, 28220 Majadahonda Madrid
[3] Unidad Microbiología Experimental, Centro de Investigación, Hospital Universitario y Politécnico la Fe, 46009 Valencia, Avenida Campanar
来源：
Current Fungal Infection Reports | 2013年 / 7卷 / 1期
关键词：
Amphotericin B; Aspergillus spp; Candida spp; CBPs; Clinical breakpoints; Clinical relevance; CLSI; Echinocandins; ECVs; Epidemiological cutoff values; EUCAST; Flucytosine; In vitro antifungal susceptibility testing; In vitro resistance; Moulds; Resistance molecular mechanisms; Triazoles; Yeasts;
D O I：
10.1007/s12281-012-0125-7
中图分类号：
学科分类号：
摘要：
The U.S. Clinical and Laboratory Standards Institute (CLSI) and the European Committee of Antimicrobial Susceptibility Testing (AFST-EUCAST) have developed broth microdilution methodologies for testing yeasts and filamentous fungi (molds). The mission of these methodologies is to identify in vitro antifungal resistance, which is accomplished by the use of either clinical breakpoints (CBPs), or to a lesser degree, epidemiologic cutoff values (ECVs). The newly adjusted and species-specific CLSI CBPs for Candida spp. versus fluconazole and voriconazole have ameliorated some of the differences between the two methodologies. In the absence of CBPs for mold testing, CLSI ECVs are available for six Aspergillus species versus the triazoles, caspofungin and amphotericin B. Recently, breakpoints were developed by the EUCAST for certain Aspergillus spp. versus amphotercin B, itraconazole and posaconazole, which to some extent are comparable to ECVs. We summarize these latest accomplishments, which have made possible the harmonization of some susceptibility cutoffs, if not methodologies for some agent/species combinations. © 2013 Springer Science+Business Media New York.
引用
收藏
页码：59 / 67
页数：8
相关论文
共 54 条
  • [1] Garcia-Vidal C., Upton A., Kirby K.A., Et al., Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: Biological risk factors for infection according to time after transplantation, Clin Infect Dis, 47, pp. 1041-1050, (2008)
  • [2] Neofytos D., Horn D., Anaissie E., Et al., Epidemiology and outcome of invasive fungal infections in adult hematopoietic stem cell transplant recipients: Analysis of multicenter PATH Alliance Registry, Clin Infect Dis., 48, pp. 265-273, (2009)
  • [3] Meis J.F., Chakrabarti A., Changing epidemiology of an emerging infection: Zygomycosis, Clin Microbiol Infect., 15, SUPPL. 5, pp. 10-14, (2009)
  • [4] Skiada S., Pagano L., Zimmerli S., Et al., Zygomycosis in Europe: Analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on zygomycosis between 2005 and 2007, Clin Microbiol Infect, 17, pp. 1859-1867, (2011)
  • [5] Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts
  • [6] Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts, Informational Supplement
  • [7] Clinical and Laboratory Standards Institute: Reference method for broth dilution antifungal susceptibility testing of filamentous fungi, Approved Standard
  • [8] Arendrup Mc C., EUCAST definitive document EDef 7.2: Method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts, Clin Microbiol Infect., 18, 7, (2012)
  • [9] EUCAST technical note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia-forming moulds, Clin Microbiol Infect, 14, pp. 982-984, (2008)
  • [10] Espinel-Ingroff A., Mold in vitro susceptibility testing: Is it ready for clinical practice?, Int J Clin Rev., 7, (2012)
123456